<DOC>
	<DOC>NCT01797874</DOC>
	<brief_summary>To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.</brief_summary>
	<brief_title>Pazopanib Maintenance for SCLC</brief_title>
	<detailed_description />
	<criteria>histologically confirmed SCLC no disease progression after 4 cycles of etoposide/platinum 1stline therapy history of 4 cycles of etoposide/platinum 1stline therapy between 21 days and 42 days since C4D1 of etoposide/platinum no symptomatic brain meta poor hepatic, renal function</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pazopanib maintenance</keyword>
	<keyword>efficacy</keyword>
	<keyword>SCLC</keyword>
</DOC>